Factive wins additional indication of multidrug-resistant streptococcus pneumoniae

Published: 2003-08-07 06:57:00

Updated: 2003-08-07 06:57:00

GeneSoft, which owns all the marketing and regulatory approval rights of LG Life Sciences' Factive (gemifloxacin) in North America and Europe, announced on July 29 that the U.S. Food and Drug Administration has approved Factive for the treatment of multidrug-resistant streptococcus pneumoniae.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK